Abstracts tagged "immunology"

Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Hanna Johnsson¹, John Cole¹, Stefan Siebert¹, Iain McInnes² and Gerard Graham¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Caroline Diorio¹, Rawan Shraim¹, Laura Vella¹, Josephine Giles², Amy Baxter², Derek Oldridge², Scott Canna¹, Sarah Henrickson¹, Kevin Mcnerney¹, Frances Balamuth¹, Chakkapong Burudpakdee¹, Jessica Lee¹, Tomas Leng¹, Alvin Farrell¹, Michele Lambert¹, Kathleen Sullivan¹, John Wherry³, David Teachey¹, Hamid Bassiri¹ and Edward Behrens¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³UPenn, Philadelphia, PA
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…
Abstract Number: 0056 • ACR Convergence 2021
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
Lihi Eder¹, Darshini Ganatra² and Vinod Chandran³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity in immune cell populations among patients with psoriatic arthritis (PsA) may determine disease expression and treatment response. The objective of this study was…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1689 • ACR Convergence 2021
Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Manoj Samant¹, Alistair Wheeler², Guang-Liang Jiang¹, Moses Njenga¹, Madeline Spiers¹, Arian Pano¹ and John F Paolini¹, ¹Kiniksa Pharmaceuticals Corp., Lexington, MA, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
Abstract Number: 0072 • ACR Convergence 2020
Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Shang-Yang Chen¹, Yidan Wang², Anna Montgomery², Salina Dominguez², Carla Cuda², Gaurav Gadhvi¹, Harris Perlman² and Deborah Winter³, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). While they are potent producers of…
Abstract Number: 0496 • ACR Convergence 2020
A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
David Patrick¹, Justin van Beusecum¹, Michelle Ormseth², Leslie J. Crofford², Sean Davies³, Sergey Dikalov¹ and David Harrison¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville
Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared…
Abstract Number: 1401 • ACR Convergence 2020
Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
Lin Shen¹, Mehrdad Matloubian¹, Theresa Kadlecek² and Arthur Weiss¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
Abstract Number: 1670 • ACR Convergence 2020
Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset
Fatima Barbar-Smiley¹, Danlei Zhou², Joanne Drew², Bi Zhou², Cagri Yildirim-Toruner², Vidya Sivaraman³, Wael Jarjour⁴, Stacy Ardoin² and Chack-Yung Yu⁵, ¹Nationwide Children's Hospital/The Ohio State University, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital, Bexley, OH, ⁴The Ohio State University, Columbus, OH, ⁵Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Hypocomplementemia is a marked feature of systemic lupus erythematosus (SLE), which may be a result of consumption initiated by immune complexes between self-nuclear antigens…
Abstract Number: 0090 • ACR Convergence 2020
110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition
Michael Lovy¹ and Andrew Dulalia¹, ¹Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) has been associated with osteoporosis, neuropathy, pernicious anemia, and low vitamin B12, and may precede multiple myeloma and…
Abstract Number: 0511 • ACR Convergence 2020
ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses
Ann Cavers¹, Yesim Ozguler², Olivier Manches³, Arshed Al-Obeidi¹, Hua Zhong¹, Beatrix Ueberheide¹, Gülen Hatemi⁴, Matthias Kugler¹ and Johannes Nowatzky⁵, ¹NYU School of Medicine, New York, ²Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, ³Inserm, U 1209, Grenoble, France, ⁴Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, ⁵New York University School of Medicine, New York, NY
Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
Abstract Number: 1402 • ACR Convergence 2020
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Kristian Juul-Madsen², John Stegmayr³, Chao Gao⁴, Tue Wenzel Kragstrup¹, Malene Hvid¹, Thomas Vorup-Jensen¹, Richard Cummings⁵, Hakon Leffler³ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark, ³Lund University, Lund, Sweden, ⁴Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center Harvard Medical School, Boston
Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…
Abstract Number: 1747 • ACR Convergence 2020
Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Arnd Kleyer¹, David Simon¹, Larissa Valor Mendez², Verena Schoenau³, Jutta Prade⁴, Marina Sergeeva⁴, Mageshvar Sulvakumar⁵, Sandra Strobelt⁴, Laura Konerth⁴, Frank Behrens⁶, Christoph Baerwald⁷, Stephanie Finzel⁸, Reinhard Voll⁹, Axel Hueber¹⁰, Julie Roesch¹¹, Eugen Feist¹², José A. P. da Silva¹³, Arnd Doerfler¹¹, Nemanja Damjanov¹⁴, Andreas Hess¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹⁰Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹¹Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁴University of Belgrade Medical School, Belgrade, Serbia, ¹⁵Institute for Experimental Pharmacology, Erlangen, ¹⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].